Parkinson's Disease

Pharmacor -- June 2008

  Introduction:

Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly. The PD therapy market features a high rate of polypharmacy that is unique among neurological disorders. High drug-treatment rates and significant unmet need combine to make it a high growth opportunity.

  Questions Answered in This Report:

Once-daily formulations of dopamine agonists recently entered the PD market. How has their entry affected the use of traditional dopamine agonists? Which patients will be the main users of once-daily dopamine agonists?

Several key therapies for PD will face generic competition over the forecast period. How much will genericization affect the PD market? How much will regulators’ efforts to contain costs affect prescribing of brand-name drugs?

By 2010, one novel nondopaminergic drug and one dopamine agonist with unique nondopaminergic effects will launch into a market dominated by dopamine precursor and dopamine agonist therapies. What is their potential impact, according to thought leaders interviewed? In which line of therapy will physicians use these agents? Will physicians use them in combination with current dopaminergic drugs or in place of them? Which patients will be the main users of these novel agents at launch? In 2017?

A therapy that can slow the course of PD remains the most critical unmet need. What are the physiological targets of neuroprotective therapies currently in development? What is the latest thought-leader opinion on emerging neuroprotective therapies? What are the biggest challenges in properly demonstrating the efficacy of neuroprotective therapies?

  Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 22 country-specific interviews with thought-leading neurologists.

Epidemiology: Prevalence of PD by country and age-group.

Emerging therapies: Phase II: 13 drugs; Phase III: 13 drugs; coverage of 12 preclinical and Phase I products with market-disrupting potential.

Market: Using market research, primary research with key opinion leaders, and our proprietary forecasting model, we forecast population sizes and drug sales for PD through 2017.